Finance

Beta
Lists
KSPHF:OTCMKTS
Kissei Pharmaceutical Co Ltd
$25.77
0.00%
(0.00) 1D
Mar 13, 11:45:41 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KSPHF...
Mkt. cap
191.75B
Avg. vol.
0.00
Volume
0.00
52-wk high
$31.90
52-wk low
$25.10
Beta
13.96
Shares outstanding
46.54M
No. of employees
2K
Mkt. cap
191.75B
Avg. vol.
0.00
Volume
0.00
52-wk high
$31.90
52-wk low
$25.10
Beta
13.96
Shares outstanding
46.54M
No. of employees
2K
News stories
From sources across the web
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include: Difelikefalin Fostamatinib Linzagolix Mitiglinide Remogliflozin etabonate Silodosin Tranilast In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79K
FoundedAug 9, 1946
HeadquartersMatsumoto, Nagano, Japan
SectorPharmaceutical industry
Websitekissei.co.jp
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
22.19B
23.64B
26.80B
24.77B
Cost of goods sold
11.11B
12.03B
14.50B
13.95B
Cost of revenue
11.11B
12.03B
14.50B
13.95B
Research and development expenses
-
-
-
22.52B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.97B
20.55B
9.15B
-15.41B
Operating expense
8.97B
20.55B
9.15B
10.07B
Total operating expenses
20.08B
32.59B
23.65B
24.02B
Operating income
2.11B
-8.95B
3.16B
756.00M
Other non operating income
16.00M
1.00M
10.00M
-10.00M
EBT including unusual items
5.75B
3.66B
4.20B
3.28B
EBT excluding unusual items
2.80B
-8.82B
3.52B
948.00M
Income tax expense
1.23B
305.00M
915.00M
482.00M
Effective tax rate
21.35%
8.33%
21.81%
14.68%
Other operating expenses
-
-
-
129.00M
Net income
4.52B
3.26B
3.23B
2.76B
Net profit margin
20.36%
13.81%
12.05%
11.16%
Earnings per share
-
-
-
-
Interest and investment income
692.00M
212.00M
614.00M
224.00M
Interest expense
-6.00M
-7.00M
-7.00M
-8.00M
Net interest expenses
686.00M
205.00M
607.00M
216.00M
Depreciation and amortization charges
-
-
-
2.83B
EBITDA
3.26B
-7.82B
4.31B
1.92B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create portfolio
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer